Regulatory Show all
July 3 | 2020

2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner

Read more
July 3 | 2020

2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner

Read more
July 2 | 2020

Bulletin from the Extraordinary General Meeting in 2cureX AB (publ)

Read more
July 2 | 2020

Kommuniké från extra bolagsstämman i 2cureX AB (publ)

Read more
June 25 | 2020

2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program

Read more
June 25 | 2020

2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program

Read more
June 17 | 2020

Notice to attend the extraordinary general meeting of 2cureX AB (publ)

Read more
June 17 | 2020

Kallelse till extra bolagsstämma i 2cureX AB (publ)

Read more
June 16 | 2020

2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients

Read more
June 16 | 2020

2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients

Read more
June 9 | 2020

Change of Certified Adviser to Redeye AB

Read more
June 9 | 2020

Byte av Certified Adviser till Redeye AB

Read more
May 29 | 2020

2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal

Read more
May 29 | 2020

2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal

Read more
May 28 | 2020

Kommuniké från årsstämma i 2cureX AB (publ)

Read more
May 28 | 2020

Communique from the Annual General Meeting in 2cureX AB (publ)

Read more
May 28 | 2020

2cureX publishes interim report for the first quarter of 2020

Read more